Search Results

1 - 10 of 20 items :

  • "acute lymphoblastic leukaemia" x
  • Microbiology and Virology x
Clear All

Abstract

The international standard protocol for acute lymphoblastic leukaemia (ALL), the most common haemato-oncological pathology at paediatric age, uses anthracyclines as antitumor agents, potentially associated with early or late onset cardiac damage. Currently, echocardiography is the gold standard in the diagnosis of cardiotoxicity, but several biomarkers are evaluated as a possible replacement, pending more extensive clinical studies. We started a prospective study in order to determine the role of two biomarkers, troponin and heart-type fatty acid binding protein, in the evaluation of cardiotoxicity in children over one year of age, diagnosed with ALL. Between February 2015 and April 2016, 20 patients were enrolled and monitored at diagnosis, during chemotherapy and four months after the end of reinduction, through cardiac evaluation and dosing of those two markers in five different points of the treatment protocol. During the first year of follow-up, the patients did not develop clinical signs of cardiac damage, but the study showed a slight increase in troponin levels during chemotherapy, with the return to baseline value after treatment cessation, and also a correlation with the total dose of anthracyclines given to the patient. On the other hand, the second biomarker, heart-type fatty acid binding protein, did not seem to be useful in detecting subclinical cardiac damage in these patients.

References 1. Imbach P, Kuhne T, Arceci RJ. Introduction: Incidence and management of childhood cancer. In Imbach P, Kuhne T, Arceci RJ (editors). Pediatric Oncology, a comprehensive guide. Springer-Verlag Berlin Heidelberg. 2011; XVII-IX DOI: 10.1007/978-3-642-20359-6 2. Sági JC, Egyed B, Kelemen A, Kutszegi N, Gezsi A, Herlitschke MA, et al. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. BMC Cancer. 2018; 18(1):704 DOI: 10.1186/s12885-018-4629-6 3. Spector LG, Ross JA

References 1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. The Lancet. 2013 Jun;381(9881):1943-55. DOI: 10.1016/S0140-6736(12)62187-4 2. Bartram CR, Schrauder A, Köhler R, Schrappe M. Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment. Dtsch Arzteblatt Int. 2012 Oct;109(40):652-8. 3. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2009 Jan;144(2):147-56. DOI: 10.1111/j.1365-2141.2008.07417.x 4. Pui C-H, Robison LL, Look AT. Acute

, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia. 2010;24(2):406-18. DOI: 10.1038/leu.2009.256 13. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. New Engl J Med. 1998;338(8):499-505. DOI: 10.1056/NEJM199802193380803 14. Mahoney DH, Shuster J, Nitschke R, Lauer SJ, Winick N, Steuber CP, et al. Intermediate-dose intravenous methotrexate with

References 1. De Braekeleer E, Douet-Guilbert N, Le Bris MJ, Basinko A, Morel F, De Braekeleer M. Gene expression profiling of adult t(4;11)(q21;q23)-associated acute lymphoblastic leukemia reveals a different signature from pediatric cases. Anticancer Res. 2012 Sep;32(9):3893-9 2. De Braekeleer M, Morel F, Le Bris MJ, Herry A, Douet-Guilbert N. The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia. Anticancer Res. 2005 May-Jun;25(3B):1931-44 3. Drexler HG, Quentmeier H, MacLeod RA. Malignant hematopoietic cell lines: in vitro models

References 1. Den Boer M.L., Harms D.O., Pieters R., Kazemier K.M., Gobel U., Körholz D., Graubner U., Haas R.J., Jorch N., Spaar H.J., Kaspers G.J., Kamps W.A., Van der Does-Van den Berg A., Van Wering E.R., Veerman A.J., Janka-Schaub G.E.: Patient stratification based on prednisolone-vincristineasparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003, 21, 262-3268. 2. Escherich G., Tröger A., Göbel U., Graubner U., Pekrun A., Jorch N., Kaspers G., Zimmermann M., zur Stadt U., Kazemier K., Pieters R., Den Boer M

N, Liu D, Jin Y. Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment. Curr Genomics. 2017;18(5):378-384. DOI: 10.2174/1389202918666170329110349 5. Fu JF, Hsu HC, Shih LY. MLL is fused to EB1 (MAPRE1), which encodes a microtubule-associated protein, in a patient with acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2005;43(2):206-10. DOI: 10.1002/gcc.20174 6. Kourlas PJ, Strout MP, Becknell B, Veronese ML, Croce CM, Theil KS et al. Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for

References 1. Elghetany TM, Bhatla T. Myelodysplastic Syndromes and Myeloproliferative Disorders. Lanzkowsky P. Hofmann I. Jeffrey M. Lipton Lanzkowsky’s Manual of Pediatric Hematology and Oncology. Sixth Edition Elsevier. 2016, London, 348-351. 2. Hasle H, Niemeyer CM, Chessells JM. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2):277-282. DOI: 10.1038/sj.leu.2402765 3. Disperati P, Ichim CV, Tkachuk D. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease

myelogenous leukemia patients harboring T315I BCR-ABL mutation. The Hematology Journal 2007, 92: 1238-1241 8. Nicolini FE, Mauro MJ, Martinelli G, Kim DW, Soverini S, Muller MC et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood, 2009, 114: 5271-5278. 9. Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Muller MC et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol, 2009, 27: 4204-4210 10

cell growth by the anti-tumor drug Ukrain. Drugs Exp Clin Res 1992, 18 , 1-4. 11. Jagiełło-Wojtowicz E., Kleinrok Z., Urbanska E.M.: Ukrain (NSC631570) in experimental and clinical studies: a review. Drugs Exp Clin Res 1998, 24 , 213-219. 12. Kang M.H., Harutyunyan N., Hall C.P., Papa R.A., Lock R.B.: Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma. Br J Haematol 2009, 145 , 389-393. 13. Kimura E., Nishimura K., Sakata K., Opa S., Kashiwagi K., Igarashi K.: Methotrexate